ZA991738B - Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists. - Google Patents

Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists.

Info

Publication number
ZA991738B
ZA991738B ZA9901738A ZA991738A ZA991738B ZA 991738 B ZA991738 B ZA 991738B ZA 9901738 A ZA9901738 A ZA 9901738A ZA 991738 A ZA991738 A ZA 991738A ZA 991738 B ZA991738 B ZA 991738B
Authority
ZA
South Africa
Prior art keywords
mixed
preparation
carboxylic acid
acid derivatives
receptor antagonists
Prior art date
Application number
ZA9901738A
Inventor
Wilhelm Amberg
Rolf Jansen Dagmar Klinge
Hartmut Riechers
Stefan Hergenroeder
Manfred Raschack
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA991738B publication Critical patent/ZA991738B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
ZA9901738A 1998-03-04 1999-03-04 Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists. ZA991738B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19809144A DE19809144A1 (en) 1998-03-04 1998-03-04 New asymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed ET¶LAMBDA¶ / ET¶B¶ receptor antagonists

Publications (1)

Publication Number Publication Date
ZA991738B true ZA991738B (en) 2000-10-11

Family

ID=7859627

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901738A ZA991738B (en) 1998-03-04 1999-03-04 Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists.

Country Status (22)

Country Link
EP (1) EP1060167A1 (en)
JP (1) JP2002505324A (en)
KR (1) KR20010041537A (en)
CN (1) CN1292782A (en)
AR (1) AR020317A1 (en)
AU (1) AU2624799A (en)
BG (1) BG104754A (en)
BR (1) BR9908401A (en)
CA (1) CA2322541A1 (en)
CO (1) CO5080805A1 (en)
DE (1) DE19809144A1 (en)
HR (1) HRP20000650A2 (en)
HU (1) HUP0101173A3 (en)
ID (1) ID26183A (en)
IL (1) IL137537A0 (en)
NO (1) NO20004351L (en)
PL (1) PL342806A1 (en)
SK (1) SK11752000A3 (en)
TR (1) TR200002545T2 (en)
TW (1) TW509676B (en)
WO (1) WO1999044998A1 (en)
ZA (1) ZA991738B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19924892A1 (en) * 1999-06-01 2000-12-07 Basf Ag New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists
ES2299436T3 (en) * 1999-10-06 2008-06-01 ABBOTT GMBH & CO. KG COMPOSITION THAT INCLUDES A TNF-ALFA INHIBITOR AND AN INTEGRINE RECEPTOR ANTAGONIST ALFAVBETA3.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411225A1 (en) * 1994-03-31 1995-10-05 Basf Ag Use of carboxylic acid derivatives as a drug
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists

Also Published As

Publication number Publication date
PL342806A1 (en) 2001-07-02
JP2002505324A (en) 2002-02-19
DE19809144A1 (en) 1999-09-09
KR20010041537A (en) 2001-05-25
AU2624799A (en) 1999-09-20
NO20004351D0 (en) 2000-09-01
BR9908401A (en) 2000-10-31
IL137537A0 (en) 2001-07-24
CN1292782A (en) 2001-04-25
ID26183A (en) 2000-12-07
CO5080805A1 (en) 2001-09-25
HRP20000650A2 (en) 2001-06-30
CA2322541A1 (en) 1999-09-10
EP1060167A1 (en) 2000-12-20
HUP0101173A3 (en) 2002-05-28
NO20004351L (en) 2000-09-01
WO1999044998A1 (en) 1999-09-10
BG104754A (en) 2001-05-31
TR200002545T2 (en) 2000-11-21
TW509676B (en) 2002-11-11
AR020317A1 (en) 2002-05-08
SK11752000A3 (en) 2001-05-10
HUP0101173A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ZA991413B (en) Substituted quinoxaline derivatives as interleukin-8 receptor antagonists.
AU5265599A (en) Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU4552497A (en) Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
HK1030939A1 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
IL135347A0 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
HUP0200080A2 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists and pharmaceutical compositions containing the compounds
AU5659498A (en) Heterocyclic carboxylic acid derivatives, their preparation ans use as endothelin receptor antagonists
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
ZA991738B (en) Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists.
ZA991411B (en) Substituted imidazo [1,2-A:3,4A']diquinolinylium interleukin-8 receptor antagonist.
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
ZA988053B (en) Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists.
HK1049151A1 (en) Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
IL137038A0 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
IL146800A0 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists
ZA989923B (en) Novel carboxylic acid derivatives with amide side chains, their preparation and use as endothelin receptor antagonists.
IL147666A0 (en) Novel carboxylic acid derivatives with 5, 6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
ZA9711305B (en) Heterocyclic carboxylic acid derivatives their preparation and use as endothelin receptor antagonists